

February 28, 2013

Press Release

Ajinomoto Pharmaceuticals Co., Ltd. , President
Pharmaceuticals”) and Eisai Co., Ltd. (Tokyo, President
announced today the Japan launch of antiosteoporotic agent

®

75 mg tablets” (risedronate sodium hydrate) following its listing on the National Health Insurance (NHI) Drug Price List on February 22. The formulation will be manufactured by Ajinomoto Pharmaceuticals and distributed by Eisai.

Risedronate sodium hydrate is a bisphosphonate agent* that is currently approved and marketed for the treatment of osteoporosis in approximately 100 countries. In Japan, once-daily and once-weekly formulations were launched in 2002 and 2007, respectively. The once-monthly

[Note to editors]

Actonel[®] 75 mg Tablets Product Outline

Product Name	Actonel [®] 75 mg tablets
Generic Name	Risedronate sodium hydrate
Indication	Osteoporosis
Dosage and Administration	The usual adult dose is 75 mg of risedronate sodium taken orally once a month on awakening, with an adequate amount of water (about 180 mL). Patients should not lie down for at least 30 minutes after taking the medication and should avoid eating and drinking except for water and administration of any other oral drugs.
Date of Approval	December 25, 2012
Listed Price	2,945.50 yen per tablet (date of NHI Drug Price List registration: February 22, 2013)
Date of Launch	February 28, 2013

